Successful leukocytapheresis therapy in a patient with rheumatoid arthritis on maintenance hemodialysis

References

• Izumi Y, Tominaga M, Iwanaga N, Huang M, Tanaka F, Aratake K et al. Twenty-four-week follow-up examination of a leukocytapheresis therapy in rheumatoid arthritis. Mod Rheumatol. 2006;16: 20–23
   PubMedGoogle Scholar
• Ueki Y, Sagawa A, Tanimura K, Yamada A, Yamamoto K, Tsuda H et al. A multicenter study of leukocytapheresis in rheumatoid arthritis. Clin Exp Rheumatol. 2007;25: 810–816.
   PubMed Web of Science ®Google Scholar
• Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T et al. Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1999;42: 431–437
   PubMed Web of Science ®Google Scholar
• Ohsawa I, Ohi H, Maruyama T, Hamada H, Tomino Y. Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient. Clin Nephrol. 2007;68: 121–124.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31: 315–324
   PubMed Web of Science ®Google Scholar
• Basile C, Montanaro A, Semeraro A. Should low-dose methotrexate therapy be prescribed to dialysis patients?. Nephrol Dial Transpl. 2002;17: 530–531
   PubMed Web of Science ®Google Scholar
• Yamashita M, Natsumeda M, Takasugi K, Ueno A, Ezawa K. Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis. Mod Rheumatol. 2008;18: 296–300
   PubMed Web of Science ®Google Scholar
• Singh R, Cuchacovich R, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol. 2002;29: 636–637.
   PubMed Web of Science ®Google Scholar
• Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006;45: 357–359
   PubMed Web of Science ®Google Scholar
• Sugioka Y, Inui K, Koike T. Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Mod Rheumatol. 2008;18: 293–295
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Arizono K. Etanercept treatment in patients with rheumatoid arthritis on dialysis. Rheumatol Int. 2010;30: 1527–1528
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Honma S, Asano Y, Minota S. Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis. Rheumatol Int. 2011;31: 559–560
   PubMed Web of Science ®Google Scholar
• Yoshihara R, Ooyama M, Nakao K, Fujimori A. Pulmonary nocardiosis in a hemodialysis patient with rheumatoid arthritis receiving etanercept. J Jpn Soc Dail Ther. 2010;43: 341–346
   Google Scholar
• Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Okada M, Ishizuka T et al. Changes in CD4+ T lymphocyte subsets in circulating blood and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. Ther Apher. 1999;3: 178–185
   PubMedGoogle Scholar
• Hidaka T, Suzuki K, Kawakami M, Okada M, Kataharada K, Shinohara T et al. Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher. 2001;16: 74–81
   PubMed Web of Science ®Google Scholar
• Yamaji K, Yang K, Tsuda H, Hashimoto H. Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther Apher. 2002;6: 402–412
   PubMedGoogle Scholar
• Hidaka T. The mechanism of the efficiency of leukocytapheresis on rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi. 2011;34: 447–455
   PubMedGoogle Scholar
• Umekita K, Hidaka T, Ueno S, Takajo I, Kai Y, Nagatomo Y et al. Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocytes-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis. Mod Rheumatol. 2009;19: 265–272
   PubMed Web of Science ®Google Scholar
• Sakai Y, Sakai S, Otsuka T, Ohno D, Murasawa T, Munakata K et al. Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab. Ther Apher Dial. 2009;13: 179–185
   PubMed Web of Science ®Google Scholar
• Hayashi W, Nishikawa Y, Tominaga T, Takashima H, Terada H, Ueki Y et al. A case of eosinophilia caused by nafamostat mesilate following leukocytapheresis in a rheumatoid arthritis patient undergoing hemodialysis. Kyushu J Rheumatol. 2006;26: 36–40.
   Google Scholar
• Nagase K, Fukunaga K, Ohnishi K, Kusaka T, Matoba Y, Sawada K. Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant. Ther Apher Dial. 2004;8: 45–51
   PubMed Web of Science ®Google Scholar
• Sato T, Imamura N, Nozaki K, Ishigaki Y. Treatment of multiple sclerosis with lymphocytapheresis using a leukocyte adsorption column. Nihon Rinsho. 1994;52: 3032–3037.
   PubMedGoogle Scholar
• Onuma S, Yamaji K, Kempe K, Ogasawara M, Ogawa T, Yang K et al. Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis. Ther Apher Dial. 2006;10: 404–411
   PubMed Web of Science ®Google Scholar
• Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, Heijde D et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60: 2262–2271
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43: 22–29
   PubMed Web of Science ®Google Scholar